ScoreHaematology
IPI and revised IPI (R-IPI) in diffuse large B-cell lymphoma
Groups the five IPI factors into three prognostic categories adapted to the rituximab era.
Updated 31 October 2026
When to use it
Patients with DLBCL at diagnosis treated with R-CHOP, to estimate survival and stratify trials.
What it needs
- Age > 60 years
- Serum LDH above the upper limit of normal
- ECOG ≥ 2
- Ann Arbor stage III–IV
- More than 1 extranodal site
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 1 | Classic IPI: low risk (0–1) |
| 2 | Classic IPI: low-intermediate risk (2) |
| 3 | Classic IPI: high-intermediate risk (3) |
| ≥ 4 | Classic IPI: high risk (4–5) |
In the app it also calculates: R-IPI group.
Practical tip
With rituximab, the classic IPI no longer identifies a group with < 50% survival; R-IPI better separates those with a very good outlook.
2 more practical tips in the app.
Reference
- Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861.
- International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987-994.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
